Gynecologic Oncology Reports最新文献_第4页

Mucinous ovarian neoplasm – outcomes of a rare tumor 卵巢黏液性肿瘤——一种罕见肿瘤的预后

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.101996

Bahareh Hamedi , Shilpa Mokshagundam , Antonio Lembo , S John Weroha , Michaela E. McGree , Amanda L. Tapia , Carrie L. Langstraat

Background

Mucinous epithelial ovarian (mEO) tumors are rare entities. In this study, we describe the management and outcomes of patients treated for mucinous borderline tumor and mucinous adenocarcinoma of the ovary.

Methods

This was a retrospective review of patients with mEO tumors from 1988 − 2021 from a single institution database. Primary outcomes were disease recurrence and death within five years post-surgery, evaluated using Cox proportional hazards and Kaplan-Meier survival analysis.

Results

We identified 262 patients with mEO tumors with a mean age of 54.9 years. One-hundred and forty-three patients (55 %) had borderline tumors and 119 (45 %) adenocarcinoma. Most patients underwent complete surgical resection (95 %).

Those with mucinous borderline tumors had favorable prognosis, with 5-year progression-free survival (PFS) and overall survival (OS) of 97%. Among patients with mucinous adenocarcinoma, 5-year PFS was 78% and 5-year OS was 80%. Fifty-seven patients with adenocarcinoma (48%) received adjuvant chemotherapy.

In univariate analysis, adenocarcinoma histology, residual disease, advanced FIGO stage (II-IV), and receipt of adjuvant chemotherapy were associated with recurrence and death within five years of surgery. While a considerable proportion of patients in both cohorts underwent gastrointestinal (GI) endoscopy, all findings were negative/benign.

Conclusions

Mucinous tumors of the ovary have overall favorable survival outcomes. In this cohort, residual disease, histopathology, and receipt of adjuvant chemotherapy were associated with disease recurrence. In addition, GI workup was of limited utility. Further study is needed to clarify ideal adjuvant treatment and GI workup.

背景：卵巢粘液上皮（mEO）肿瘤是一种罕见的肿瘤。在这项研究中，我们描述了治疗卵巢粘液交界性肿瘤和粘液腺癌的患者的管理和结果。方法回顾性分析1988 - 2021年单一机构数据库中mEO肿瘤患者。主要结局是术后5年内疾病复发和死亡，采用Cox比例风险和Kaplan-Meier生存分析进行评估。结果262例mEO肿瘤患者，平均年龄54.9岁。143例（55%）为交界性肿瘤，119例（45%）为腺癌。大多数患者接受了完全手术切除（95%）。黏液交界性肿瘤患者预后良好，5年无进展生存期（PFS）和总生存期（OS）为97%。粘液腺癌患者的5年PFS为78%，5年OS为80%。57例腺癌患者（48%）接受了辅助化疗。在单因素分析中，腺癌组织学、残留病变、晚期FIGO分期（II-IV）和接受辅助化疗与手术后5年内的复发和死亡相关。虽然两个队列中相当比例的患者接受了胃肠道（GI）内窥镜检查，但所有结果均为阴性/良性。结论卵巢黏液性肿瘤总体生存率较好。在这个队列中，残留疾病、组织病理学和接受辅助化疗与疾病复发有关。此外，GI检查的作用有限。理想的辅助治疗和GI检查需要进一步的研究。

{"title":"Mucinous ovarian neoplasm – outcomes of a rare tumor","authors":"Bahareh Hamedi , Shilpa Mokshagundam , Antonio Lembo , S John Weroha , Michaela E. McGree , Amanda L. Tapia , Carrie L. Langstraat","doi":"10.1016/j.gore.2025.101996","DOIUrl":"10.1016/j.gore.2025.101996","url":null,"abstract":"<div><h3>Background</h3><div>Mucinous epithelial ovarian (mEO) tumors are rare entities. In this study, we describe the management and outcomes of patients treated for mucinous borderline tumor and mucinous adenocarcinoma of the ovary.</div></div><div><h3>Methods</h3><div>This was a retrospective review of patients with mEO tumors from 1988 − 2021 from a single institution database. Primary outcomes were disease recurrence and death within five years post-surgery, evaluated using Cox proportional hazards and Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>We identified 262 patients with mEO tumors with a mean age of 54.9 years. One-hundred and forty-three patients (55 %) had borderline tumors and 119 (45 %) adenocarcinoma. Most patients underwent complete surgical resection (95 %).</div><div>Those with mucinous borderline tumors had favorable prognosis, with 5-year progression-free survival (PFS) and overall survival (OS) of 97%. Among patients with mucinous adenocarcinoma, 5-year PFS was 78% and 5-year OS was 80%. Fifty-seven patients with adenocarcinoma (48%) received adjuvant chemotherapy.</div><div>In univariate analysis, adenocarcinoma histology, residual disease, advanced FIGO stage (II-IV), and receipt of adjuvant chemotherapy were associated with recurrence and death within five years of surgery. While a considerable proportion of patients in both cohorts underwent gastrointestinal (GI) endoscopy, all findings were negative/benign.</div></div><div><h3>Conclusions</h3><div>Mucinous tumors of the ovary have overall favorable survival outcomes. In this cohort, residual disease, histopathology, and receipt of adjuvant chemotherapy were associated with disease recurrence. In addition, GI workup was of limited utility. Further study is needed to clarify ideal adjuvant treatment and GI workup.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101996"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review 类卵巢癌合并类癌性心脏综合征1例报告并文献复习

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.101997

Minyoung Jang , Lakeisha Mulugeta-Gordon , Joseph Carver , Natalie Tupper , Julie Barbera , Lauren Schwartz , Nawar Latif

Background

Primary ovarian carcinoid tumors are rare neuroendocrine neoplasms comprising <0.1% of ovarian tumors and 1% of all carcinoid tumors. Up to 30% present with carcinoid syndrome, and approximately one-quarter of these develop carcinoid heart syndrome. Unlike gastrointestinal carcinoid tumors, ovarian lesions can cause carcinoid syndrome without hepatic metastases due to direct venous drainage into the systemic circulation.

Case

A 46-year-old woman presented with abdominal discomfort, new onset hypertension, and lower extremity edema. Imaging revealed a 16.8 cm right adnexal mass with mixed solid and cystic components. Echocardiography demonstrated torrential tricuspid regurgitation related to thickened, immobile leaflets, consistent with carcinoid heart syndrome. Serum serotonin and chromogranin A were markedly elevated. She underwent exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic and para-aortic lymphadenectomy, and omental biopsy. Pathology showed a carcinoid tumor arising in a mature cystic teratoma, confined to the right ovary (FIGO stage IA). Immunohistochemistry confirmed neuroendocrine differentiation (synaptophysin, chromogranin positive). Postoperatively, chromogranin A normalized, serotonin decreased, and proBNP improved. Three months later, she underwent successful bioprosthetic tricuspid valve replacement with ongoing Cardiology follow up.

Discussion

This case illustrates that ovarian carcinoid tumors may present with minimal symptoms despite significant cardiac involvement. Early cardiac evaluation is warranted in suspected carcinoid tumors to identify carcinoid heart syndrome. Overall survival is generally favorable for early stage ovarian carcinoid tumors. Long-term cardiac prognosis is determined by right ventricular function and presence of residual tumor after resection. Management requires individualized and multidisciplinary surgical planning, balancing tumor resection with timely cardiac intervention.

原发性卵巢类癌是一种罕见的神经内分泌肿瘤，占卵巢肿瘤的0.1%，占所有类癌的1%。高达30%的人表现为类癌综合征，其中约四分之一的人发展为类癌心脏综合征。与胃肠道类癌不同，卵巢病变由于静脉直接引流进入体循环，可引起无肝转移的类癌综合征。病例1:46岁女性，腹部不适，新发高血压，下肢水肿。影像显示右侧附件16.8 cm肿块，有实性和囊性混合成分。超声心动图显示剧烈的三尖瓣反流与增厚、不动的小叶有关，符合类癌心脏综合征。血清5 -羟色胺和嗜铬粒蛋白A明显升高。她接受了剖腹探查、全腹子宫切除术、双侧输卵管卵巢切除术、右侧骨盆和主动脉旁淋巴结切除术和大网膜活检。病理显示成熟囊性畸胎瘤的类癌，局限于右侧卵巢（FIGO IA期）。免疫组化证实神经内分泌分化（synaptophysin， chromogranin阳性）。术后，色粒蛋白A正常化，血清素降低，proBNP改善。三个月后，她成功接受了生物假体三尖瓣置换术，并进行了心脏病学随访。本病例表明，尽管严重累及心脏，但卵巢类癌可能表现为轻微症状。对于疑似类癌肿瘤，早期心脏评估是必要的，以确定类癌心脏综合征。早期类卵巢肿瘤的总体生存率通常是有利的。长期心脏预后是由右心室功能和肿瘤切除后是否存在残余肿瘤决定的。治疗需要个体化和多学科的手术计划，平衡肿瘤切除和及时的心脏介入治疗。

{"title":"Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review","authors":"Minyoung Jang , Lakeisha Mulugeta-Gordon , Joseph Carver , Natalie Tupper , Julie Barbera , Lauren Schwartz , Nawar Latif","doi":"10.1016/j.gore.2025.101997","DOIUrl":"10.1016/j.gore.2025.101997","url":null,"abstract":"<div><h3>Background</h3><div>Primary ovarian carcinoid tumors are rare neuroendocrine neoplasms comprising <0.1% of ovarian tumors and 1% of all carcinoid tumors. Up to 30% present with carcinoid syndrome, and approximately one-quarter of these develop carcinoid heart syndrome. Unlike gastrointestinal carcinoid tumors, ovarian lesions can cause carcinoid syndrome without hepatic metastases due to direct venous drainage into the systemic circulation.</div></div><div><h3>Case</h3><div>A 46-year-old woman presented with abdominal discomfort, new onset hypertension, and lower extremity edema. Imaging revealed a 16.8 cm right adnexal mass with mixed solid and cystic components. Echocardiography demonstrated torrential tricuspid regurgitation related to thickened, immobile leaflets, consistent with carcinoid heart syndrome. Serum serotonin and chromogranin A were markedly elevated. She underwent exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic and para-aortic lymphadenectomy, and omental biopsy. Pathology showed a carcinoid tumor arising in a mature cystic teratoma, confined to the right ovary (FIGO stage IA). Immunohistochemistry confirmed neuroendocrine differentiation (synaptophysin, chromogranin positive). Postoperatively, chromogranin A normalized, serotonin decreased, and proBNP improved. Three months later, she underwent successful bioprosthetic tricuspid valve replacement with ongoing Cardiology follow up.</div></div><div><h3>Discussion</h3><div>This case illustrates that ovarian carcinoid tumors may present with minimal symptoms despite significant cardiac involvement. Early cardiac evaluation is warranted in suspected carcinoid tumors to identify carcinoid heart syndrome. Overall survival is generally favorable for early stage ovarian carcinoid tumors. Long-term cardiac prognosis is determined by right ventricular function and presence of residual tumor after resection. Management requires individualized and multidisciplinary surgical planning, balancing tumor resection with timely cardiac intervention.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101997"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and Olaparib 一个快速进展的原位卵巢癌模型揭示了靶向axl的纳米体和奥拉帕尼的协同抗肿瘤作用

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.101998

Aarushi A. Caro , Alícia Gordún Peiró , Eva Hadadi , Yani Berckmans , Yvon Elkrim , Ayla Debraekeleer , Gisèle Mateu Cabrera , Kim De Veirman , An Coosemans , Damya Laoui

Objective

Ovarian cancer (OC) is the deadliest gynecological malignancy, with patients experiencing late diagnosis and high recurrence. AXL is highly expressed in OC and correlates with worse prognosis. We aim to evaluate the use of AXL-targeting nanobodies as a novel therapeutic modality to inhibit the AXL-GAS6 axis in OC.

Methods

ID8-fLuc cells were in vivo passaged three times to obtain the fast-progressing P3 ID8 Thy1.1 cell line. The expression of AXL in ID8 lines was assessed by flow cytometry and immunofluorescence, while serum GAS6 levels in tumor-bearing and naïve mice were measured by ELISA. Using in silico analyses, we correlated AXL and GAS6 expression with OC patient outcomes and assessed AXL expression in different tissues and patient cohorts. Orthotopic ovarian tumors were processed to a single cell suspension and treated in vitro with the nanobody (AXL-Fc), a PARP inhibitor (Olaparib), or controls (PBS or DMSO) for 24 h or 72 h, followed by flow cytometry to assess stages of cell death and cancer cell proliferation.

Results

In vivo passaging of ID8-fLuc cells resulted in a faster-progressing P3 ID8 Thy1.1 cell line that recapitulates stages I-III observed in OC patients. In OC patients, AXL and GAS6 genes are highly expressed in primary and metastatic tumors, and enriched in platinum-resistant patients. AXL-Fc induces necrosis in OC cells from orthotopic ovarian tumors. AXL-Fc synergizes with Olaparib, resulting in decreased OC cell proliferation.

Conclusions

Leveraging the synergistic effects of AXL-Fc with Olaparib, we propose a new AXL-targeting treatment approach for OC that warrants further investigation.

目的卵巢癌是最致命的妇科恶性肿瘤，诊断晚，复发率高。AXL在OC中高表达，预后较差。我们的目的是评估使用靶向axl的纳米体作为一种新的治疗方式来抑制OC中的AXL-GAS6轴。方法sid8 - fluc细胞在体内传代3次，获得快速进展的P3 ID8 Thy1.1细胞系。采用流式细胞术和免疫荧光法检测ID8细胞系中AXL的表达，ELISA法检测荷瘤小鼠和naïve小鼠血清中GAS6的表达。通过计算机分析，我们将AXL和GAS6的表达与OC患者的预后相关联，并评估了AXL在不同组织和患者队列中的表达。将原位卵巢肿瘤处理成单细胞悬液，用纳米体（AXL-Fc）、PARP抑制剂（Olaparib）或对照组（PBS或DMSO）在体外处理24小时或72小时，然后用流式细胞术评估细胞死亡和癌细胞增殖的阶段。结果ID8- fluc细胞的体内传代导致P3 - ID8 Thy1.1细胞系进展更快，重现了在OC患者中观察到的I-III期。在OC患者中，AXL和GAS6基因在原发和转移性肿瘤中高表达，在铂耐药患者中富集。AXL-Fc诱导原位卵巢肿瘤OC细胞坏死。AXL-Fc与奥拉帕尼协同作用，导致OC细胞增殖下降。结论利用AXL-Fc与奥拉帕尼的协同作用，我们提出了一种新的靶向axl治疗OC的方法，值得进一步研究。

{"title":"A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and Olaparib","authors":"Aarushi A. Caro , Alícia Gordún Peiró , Eva Hadadi , Yani Berckmans , Yvon Elkrim , Ayla Debraekeleer , Gisèle Mateu Cabrera , Kim De Veirman , An Coosemans , Damya Laoui","doi":"10.1016/j.gore.2025.101998","DOIUrl":"10.1016/j.gore.2025.101998","url":null,"abstract":"<div><h3>Objective</h3><div>Ovarian cancer (OC) is the deadliest gynecological malignancy, with patients experiencing late diagnosis and high recurrence. AXL is highly expressed in OC and correlates with worse prognosis. We aim to evaluate the use of AXL-targeting nanobodies as a novel therapeutic modality to inhibit the AXL-GAS6 axis in OC.</div></div><div><h3>Methods</h3><div>ID8-fLuc cells were <em>in vivo</em> passaged three times to obtain the fast-progressing P3 ID8 Thy1.1 cell line. The expression of AXL in ID8 lines was assessed by flow cytometry and immunofluorescence, while serum GAS6 levels in tumor-bearing and naïve mice were measured by ELISA. Using <em>in silico</em> analyses, we correlated AXL and GAS6 expression with OC patient outcomes and assessed AXL expression in different tissues and patient cohorts. Orthotopic ovarian tumors were processed to a single cell suspension and treated <em>in vitro</em> with the nanobody (AXL-Fc), a PARP inhibitor (Olaparib), or controls (PBS or DMSO) for 24 h or 72 h, followed by flow cytometry to assess stages of cell death and cancer cell proliferation.</div></div><div><h3>Results</h3><div><em>In vivo</em> passaging of ID8-fLuc cells resulted in a faster-progressing P3 ID8 Thy1.1 cell line that recapitulates stages I-III observed in OC patients. In OC patients, <em>AXL</em> and <em>GAS6</em> genes are highly expressed in primary and metastatic tumors, and enriched in platinum-resistant patients. AXL-Fc induces necrosis in OC cells from orthotopic ovarian tumors. AXL-Fc synergizes with Olaparib, resulting in decreased OC cell proliferation.</div></div><div><h3>Conclusions</h3><div>Leveraging the synergistic effects of AXL-Fc with Olaparib, we propose a new AXL-targeting treatment approach for OC that warrants further investigation.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101998"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy 绝经后女性体内衍生性卵巢卵黄囊肿瘤：个体化化疗持久缓解一例报告

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.101989

Vinita Popat , Adam Rucker , Joseph W. Carlson , Aimee Keegan , Lorna Rodriguez-Rodriguez

Background

Somatically derived ovarian yolk sac tumors (SD-YSTs) in postmenopausal women are rare and typically present with advanced-stage disease, often carrying a poor prognosis.

Case

We describe a 74-year-old woman with stage IIIB SD-YST who underwent complete surgical resection followed by cisplatin-etoposide chemotherapy, with bleomycin omitted due to frailty. Chemotherapy scheduling was modified in real time according to alpha-fetoprotein (AFP) kinetics, with treatment intervals shortened from 21 to 14 days after AFP levels rose between early cycles. Despite dose reductions due to thrombocytopenia, AFP levels normalized after cycle 3, and treatment was discontinued after cycle 4.

Outcome

The patient has remained disease-free for over five years with ongoing surveillance.

Conclusion

This case underscores the potential for long-term remission in SD-YST with platinum-based therapy, even when standard regimens require modification for older or frail patients. It highlights the value of biomarker-guided treatment adjustments to optimize chemotherapy timing in rare ovarian malignancies.

卵巢卵黄囊肿瘤（SD-YSTs）在绝经后妇女中很少见，通常出现在晚期，通常预后较差。病例：我们描述了一位74岁的IIIB期SD-YST女性患者，她接受了完整的手术切除，随后进行了顺铂-依托泊苷化疗，由于虚弱而省略了博来霉素。化疗计划根据甲胎蛋白（AFP）动力学实时修改，治疗间隔从早期周期甲胎蛋白水平升高后的21天缩短到14天。尽管由于血小板减少导致剂量减少，但AFP水平在第3周期后恢复正常，并在第4周期后停止治疗。结果：患者在持续监测的情况下无病已超过5年。结论：该病例强调了铂基治疗SD-YST长期缓解的潜力，即使标准方案需要对老年或体弱患者进行修改。它强调了生物标志物引导的治疗调整的价值，以优化罕见卵巢恶性肿瘤的化疗时机。

{"title":"Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy","authors":"Vinita Popat , Adam Rucker , Joseph W. Carlson , Aimee Keegan , Lorna Rodriguez-Rodriguez","doi":"10.1016/j.gore.2025.101989","DOIUrl":"10.1016/j.gore.2025.101989","url":null,"abstract":"<div><h3>Background</h3><div>Somatically derived ovarian yolk sac tumors (SD-YSTs) in postmenopausal women are rare and typically present with advanced-stage disease, often carrying a poor prognosis.</div></div><div><h3>Case</h3><div>We describe a 74-year-old woman with stage IIIB SD-YST who underwent complete surgical resection followed by cisplatin-etoposide chemotherapy, with bleomycin omitted due to frailty. Chemotherapy scheduling was modified in real time according to alpha-fetoprotein (AFP) kinetics, with treatment intervals shortened from 21 to 14 days after AFP levels rose between early cycles. Despite dose reductions due to thrombocytopenia, AFP levels normalized after cycle 3, and treatment was discontinued after cycle 4.</div></div><div><h3>Outcome</h3><div>The patient has remained disease-free for over five years with ongoing surveillance.</div></div><div><h3>Conclusion</h3><div>This case underscores the potential for long-term remission in SD-YST with platinum-based therapy, even when standard regimens require modification for older or frail patients. It highlights the value of biomarker-guided treatment adjustments to optimize chemotherapy timing in rare ovarian malignancies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101989"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Etoposide combined with anlotinib and sintilimab successfully achieved long term progression-free survival in platinum-refractory ovarian cancer: A case report 依托泊苷联合安洛替尼和辛替单抗治疗铂难治性卵巢癌成功实现长期无进展生存：1例报告

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.101999

Luying Zhang, Yuxin Wang, Cang Qiu, Yang Li, Kelei Zhao, Xiaohan Yuan, Yanting Liu, Ping Lu, Min Zhang

Background

Platinum-refractory ovarian cancer (PROC) is extremely malignant and aggressive. Patients typically have a diminished quality of life and limited survival, with an overall survival (OS) of less than one year. Until early 2024, bevacizumab remains the only targeted agent approved in China for the treatment of PROC. The standard regimen for PROC in China is non-platinum single-agent chemotherapy, or chemotherapy combined with bevacizumab. However, these therapies have not achieved satisfactory clinical outcomes.

Case presentation

A 63-year-old woman presented with an incidentally detected left neck mass. Ultrasound-guided biopsy revealed high-grade serous ovarian carcinoma. She received first-line bevacizumab plus platinum-based chemotherapy but showed disease progression after two cycles, consistent with platinum-refractory ovarian cancer. After similarly failing second-line gemcitabine therapy (2 cycles), she achieved complete response (CR) and maintained progression-free survival (PFS) for 23.9 months with third-line etoposide combined with anlotinib and sintilimab.

Conclusion

This case demonstrates that the combination of etoposide, anlotinib, and sintilimab can induce sustained CR in platinum-refractory ovarian cancer, achieving remarkable 23.9-month PFS. The synergistic activity of this regimen successfully reversed multidrug resistance and may redefine third-line therapeutic strategies for this challenging population.

背景铂难治性卵巢癌（PROC）是一种极具恶性和侵袭性的肿瘤。患者通常生活质量下降，生存期有限，总生存期（OS）不到一年。直到2024年初，贝伐单抗仍是中国唯一批准用于治疗PROC的靶向药物，中国PROC的标准方案是非铂单药化疗，或化疗联合贝伐单抗。然而，这些疗法并没有取得令人满意的临床效果。病例表现一名63岁女性，偶然发现左颈部肿块。超声引导下活检显示高级别浆液性卵巢癌。她接受了一线贝伐单抗加铂基化疗，但在两个周期后出现疾病进展，与铂难治性卵巢癌一致。在二线吉西他滨治疗同样失败（2个周期）后，她获得了完全缓解（CR），并在三线依托泊苷联合安洛替尼和辛替单抗的情况下维持了23.9个月的无进展生存期（PFS）。结论依托泊苷、安洛替尼、辛替单抗联合治疗铂难治性卵巢癌可诱导持续CR，取得显著的23.9个月PFS。该方案的协同作用成功逆转了多药耐药，并可能重新定义针对这一具有挑战性人群的三线治疗策略。

{"title":"Etoposide combined with anlotinib and sintilimab successfully achieved long term progression-free survival in platinum-refractory ovarian cancer: A case report","authors":"Luying Zhang, Yuxin Wang, Cang Qiu, Yang Li, Kelei Zhao, Xiaohan Yuan, Yanting Liu, Ping Lu, Min Zhang","doi":"10.1016/j.gore.2025.101999","DOIUrl":"10.1016/j.gore.2025.101999","url":null,"abstract":"<div><h3>Background</h3><div>Platinum-refractory ovarian cancer (PROC) is extremely malignant and aggressive. Patients typically have a diminished quality of life and limited survival, with an overall survival(OS)of less than one year. Until early 2024, bevacizumab remains the only targeted agent approved in China for the treatment of PROC. The standard regimen for PROC in China is non-platinum single-agent chemotherapy, or chemotherapy combined withbevacizumab. However, these therapies have not achievedsatisfactory clinical outcomes.</div></div><div><h3>Case presentation</h3><div>A 63-year-old woman presented with an incidentally detected left neck mass. Ultrasound-guided biopsy revealed high-grade serous ovarian carcinoma. She received first-line bevacizumab plus platinum-based chemotherapy but showed disease progression after two cycles, consistent with platinum-refractory ovarian cancer. After similarly failing second-line gemcitabine therapy (2 cycles), she achieved complete response (CR) and maintained progression-free survival (PFS) for 23.9 months with third-line etoposide combined with anlotinib and sintilimab.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that the combination of etoposide, anlotinib, and sintilimab can induce sustained CR in platinum-refractory ovarian cancer, achieving remarkable 23.9-month PFS. The synergistic activity of this regimen successfully reversed multidrug resistance and may redefine third-line therapeutic strategies for this challenging population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101999"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive “targeted” surgery? 考虑到HIPEC中同源重组缺陷的状况：分子检测有朝一日能推动“靶向”手术吗？

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.102001

Sarah P. Huepenbecker , Katherine C. Fuh

引用次数: 0

Attitudes towards opportunistic salpingectomy among patients planned to undergo non-gynecologic intra-abdominal surgery 计划行非妇科腹腔手术患者对机会性输卵管切除术的态度

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-12-01 DOI: 10.1016/j.gore.2025.102000

Monali S. Ardeshna , Lauren Dori , Benjamin Margolis

Objective

To evaluate the knowledge of and interest in opportunistic salpingectomy (OS) in patients undergoing non-gynecologic abdominal surgery.

Methods

English-speaking patients aged 18 or older with fallopian tubes who were scheduled for upcoming abdominal general, colorectal, or bariatric surgery were approached. A phone-administered questionnaire was used to collect demographics, clinical history, knowledge of OS, and likelihood to undergo OS if offered. Chi-square tests, Fisher’s exact tests, and odds ratios were calculated in R.

Results

153 patients were contacted, of which 68 were eligible and agreed to participate (44.4 % response rate). Of the 68 participants, 60 (88.2 %) were considered OS candidates (not interested in future fertility). The average age was 58, and 97 % of respondents self-identified as White. Forty-five respondents (75.0 %) were post-menopausal, 11 (18.3 %) had undergone a hysterectomy, and 16 (26.7 %) had undergone permanent contraception. Only 12 (20.0 %) knew OS reduces ovarian cancer risk. Among OS candidates, 15 (25.0 %) were likely to undergo OS during their upcoming surgery if offered. Predictors of likelihood to undergo OS during surgery include awareness of OS (50.0 % vs 19.0 %, OR 4.33, 95 % CI: 1.13–16.61, p = 0.025), family history of ovarian cancer (66.7 % vs 20.4 %, OR 7.82, 95 % CI: 1.26–48.35, p = 0.030), and interest in permanent contraception (100 % vs 25 %, p = 0.044).

Conclusion

Among patients with fallopian tubes undergoing non-gynecologic abdominal surgery, most were appropriate candidates for OS. Prior awareness of OS, family history of ovarian cancer, and interest in permanent contraception were associated with a greater interest in OS.

目的评价非妇科腹部手术患者对机会性输卵管切除术（OS）的认知和兴趣。方法：研究对象为年龄在18岁及以上的输卵管患者，这些患者计划进行腹部手术、结直肠手术或减肥手术。使用电话管理问卷收集人口统计资料、临床病史、OS知识以及接受OS的可能性。结果联系了153例患者，其中68例符合条件并同意参与（有效率44.4%）。在68名参与者中，60名（88.2%）被认为是OS候选人（对未来生育不感兴趣）。平均年龄为58岁，97%的受访者自认为是白人。45例（75.0%）为绝经后患者，11例（18.3%）为子宫切除术患者，16例（26.7%）为永久性避孕患者。只有12人（20.0%）知道OS可以降低卵巢癌风险。在手术候选者中，有15人（25.0%）可能在即将进行的手术中接受手术。手术期间发生OS的可能性预测因素包括对OS的了解（50.0% vs 19.0%, OR 4.33, 95% CI: 1.13-16.61, p = 0.025）、卵巢癌家族史（66.7% vs 20.4%, OR 7.82, 95% CI: 1.26-48.35, p = 0.030）和对永久避孕的兴趣（100% vs 25%, p = 0.044）。结论输卵管行非妇科腹腔手术的患者中，绝大多数为合适的手术对象。先前对卵巢癌的认识、卵巢癌家族史和对永久避孕的兴趣与对卵巢癌的更大兴趣相关。

{"title":"Attitudes towards opportunistic salpingectomy among patients planned to undergo non-gynecologic intra-abdominal surgery","authors":"Monali S. Ardeshna , Lauren Dori , Benjamin Margolis","doi":"10.1016/j.gore.2025.102000","DOIUrl":"10.1016/j.gore.2025.102000","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the knowledge of and interest in opportunistic salpingectomy (OS) in patients undergoing non-gynecologic abdominal surgery.</div></div><div><h3>Methods</h3><div>English-speaking patients aged 18 or older with fallopian tubes who were scheduled for upcoming abdominal general, colorectal, or bariatric surgery were approached. A phone-administered questionnaire was used to collect demographics, clinical history, knowledge of OS, and likelihood to undergo OS if offered. Chi-square tests, Fisher’s exact tests, and odds ratios were calculated in R.</div></div><div><h3>Results</h3><div>153 patients were contacted, of which 68 were eligible and agreed to participate (44.4 % response rate). Of the 68 participants, 60 (88.2 %) were considered OS candidates (not interested in future fertility). The average age was 58, and 97 % of respondents self-identified as White. Forty-five respondents (75.0 %) were post-menopausal, 11 (18.3 %) had undergone a hysterectomy, and 16 (26.7 %) had undergone permanent contraception. Only 12 (20.0 %) knew OS reduces ovarian cancer risk. Among OS candidates, 15 (25.0 %) were likely to undergo OS during their upcoming surgery if offered. Predictors of likelihood to undergo OS during surgery include awareness of OS (50.0 % vs 19.0 %, OR 4.33, 95 % CI: 1.13–16.61, p = 0.025), family history of ovarian cancer (66.7 % vs 20.4 %, OR 7.82, 95 % CI: 1.26–48.35, p = 0.030), and interest in permanent contraception (100 % vs 25 %, p = 0.044).</div></div><div><h3>Conclusion</h3><div>Among patients with fallopian tubes undergoing non-gynecologic abdominal surgery, most were appropriate candidates for OS. Prior awareness of OS, family history of ovarian cancer, and interest in permanent contraception were associated with a greater interest in OS.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 102000"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robot-assisted transvaginal staging surgery using da Vinci SP for suspected ovarian borderline tumor: a case report 机器人辅助经阴道分期手术使用达芬奇SP怀疑卵巢交界性肿瘤：1例报告

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-11-17 DOI: 10.1016/j.gore.2025.101987

Naofumi Higuchi, Kiyoshi Kanno, Tomoka Kashiwabara, Taisuke Iwata, Yudai Sawai, Hiroshi Onji, Ryo Taniguchi, Masaaki Andou

Background

Minimally invasive surgery is increasingly being applied in selected cases of ovarian borderline tumors and ovarian cancer. With the introduction of the da Vinci SP (SP) system, our institution began robot-assisted vNOTES (RAvNOTES) in 2023. This approach may overcome the limitations of conventional vNOTES, particularly limited triangulation (Lowenstein et al., 2020, Hurni et al., 2022, Hurni and Huber, 2023). We describe staging surgery for a suspected ovarian borderline tumor, performed using RAvNOTES.

背景：微创手术越来越多地应用于卵巢交界性肿瘤和卵巢癌的治疗。随着达芬奇SP （da Vinci SP）系统的引入，我们的机构于2023年开始了机器人辅助vNOTES （RAvNOTES）。这种方法可以克服传统vNOTES的局限性，特别是有限的三角测量（Lowenstein等人，2020年，Hurni等人，2022年，Hurni和Huber， 2023年）。我们描述分期手术的怀疑卵巢交界性肿瘤，进行了使用RAvNOTES。

引用次数: 0

MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis MECOM扩增子宫内膜癌，一个新的亚群的拷贝数高的肿瘤相关的不良预后

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-11-16 DOI: 10.1016/j.gore.2025.101993

Shariska P. Harrington , Jacqueline Romani , Aminah Jatoi , S.John Weroha , Andrea Mariani , William A. Cliby , Jamie N. Bakkum-Gamez , Dineo Khabele , Alexandre Gaspar-Maia

Objective

Copy number high (CNH) endometrial cancer (EC) is an aggressive molecular subgroup characterized by TP53 mutations and relative chemoresistance. CNH EC with cyclin E1 gene (CCNE1) amplification and erythroblastic oncogene B (ERBB2) amplification are associated with poor clinical outcomes. MECOM, a complex locus of MDS1 (myelodysplasia syndrome 1) and EVI1 (ecotropic virus integration site 1), has recently been associated with poor prognosis in ovarian cancer. Our objective was to evaluate clinical outcomes of MECOM, CCNE1 and ERBB2 amplified ECs and to provide a literature review on the role of MECOM in gynecologic cancers.

Methods

Copy number variation and molecular subtype classification were extracted from The Cancer Genome Atlas for 529 ECs. Amplification status was determined for MECOM, CCNE1 and ERBB2. Measured clinical outcomes were overall and progression-free survival, covariates included race, stage at diagnosis, and tumor histology. A comprehensive search of peer-reviewed articles was undertaken to summarize evidence on the role of MECOM in gynecologic cancers.

Results

Of all ECs profiled, MECOM was the most frequently amplified gene. Notably, 35% of CNH ECs were MECOM amplified. In multivariate analysis, MECOM amplification without co-amplification of CCNE1 or ERBB2 was associated with an increased risk of death and recurrence, HR 2.3 [1.17–4.62], p = 0.0163 and HR 2.07 [1.08–3.98], p = 0.0282, respectively. The literature review identified 19 relevant studies with inconsistent evidence on MECOM’s role in carcinogenesis.

Conclusions

ECs with MECOM amplification are associated with poor clinical outcomes, even in the absence of CCNE1 or ERBB2 amplification. The current literature is limited, and further studies are warranted to determine the role of MECOM amplification in ECs.

目的高拷贝数（CNH）子宫内膜癌（EC）是一种以TP53突变和相对化疗耐药为特征的侵袭性分子亚群。伴有细胞周期蛋白E1基因（CCNE1）扩增和红母细胞癌基因B （ERBB2）扩增的CNH EC与较差的临床结果相关。MECOM是MDS1（骨髓增生异常综合征1）和EVI1（亲生态病毒整合位点1）的复杂位点，最近发现与卵巢癌预后不良相关。我们的目的是评估MECOM、CCNE1和ERBB2扩增的ECs的临床结果，并对MECOM在妇科癌症中的作用进行文献综述。方法从肿瘤基因组图谱中提取529例ECs的数量变异和分子亚型分类。测定MECOM、CCNE1和ERBB2的扩增情况。测量的临床结果是总生存期和无进展生存期，协变量包括种族、诊断阶段和肿瘤组织学。我们对同行评议的文章进行了全面检索，总结了MECOM在妇科癌症中作用的证据。结果在所分析的ECs中，MECOM是扩增频率最高的基因。值得注意的是，35%的CNH ec是MECOM扩增的。在多因素分析中，MECOM扩增而不同时扩增CCNE1或ERBB2与死亡和复发风险增加相关，HR分别为2.3 [1.17-4.62],p = 0.0163； HR为2.07 [1.08-3.98],p = 0.0282。文献综述确定了19项有关MECOM在致癌作用方面证据不一致的相关研究。结论即使没有CCNE1或ERBB2扩增，伴有MECOM扩增的sc也与较差的临床结果相关。目前的文献是有限的，需要进一步的研究来确定MECOM扩增在ECs中的作用。

{"title":"MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis","authors":"Shariska P. Harrington , Jacqueline Romani , Aminah Jatoi , S.John Weroha , Andrea Mariani , William A. Cliby , Jamie N. Bakkum-Gamez , Dineo Khabele , Alexandre Gaspar-Maia","doi":"10.1016/j.gore.2025.101993","DOIUrl":"10.1016/j.gore.2025.101993","url":null,"abstract":"<div><h3>Objective</h3><div>Copy number high (CNH) endometrial cancer (EC) is an aggressive molecular subgroup characterized by TP53 mutations and relative chemoresistance. CNH EC with cyclin E1 gene (<em>CCNE1</em>) amplification and erythroblastic oncogene B <em>(ERBB2)</em> amplification are associated with poor clinical outcomes. <em>MECOM</em>, a complex locus of MDS1 (myelodysplasia syndrome 1) and EVI1 (ecotropic virus integration site 1), has recently been associated with poor prognosis in ovarian cancer. Our objective was to evaluate clinical outcomes of <em>MECOM</em>, <em>CCNE1</em> and <em>ERBB2</em> amplified ECs and to provide a literature review on the role of <em>MECOM</em> in gynecologic cancers.</div></div><div><h3>Methods</h3><div>Copy number variation and molecular subtype classification were extracted from The Cancer Genome Atlas for 529 ECs. Amplification status was determined for <em>MECOM</em>, <em>CCNE1</em> and <em>ERBB2.</em> Measured clinical outcomes were overall and progression-free survival, covariates included race, stage at diagnosis, and tumor histology. A comprehensive search of peer-reviewed articles was undertaken to summarize evidence on the role of <em>MECOM</em> in gynecologic cancers.</div></div><div><h3>Results</h3><div>Of all ECs profiled, <em>MECOM</em> was the most frequently amplified gene. Notably, 35% of CNH ECs were <em>MECOM</em> amplified. In multivariate analysis, <em>MECOM</em> amplification without co-amplification of <em>CCNE1</em> or <em>ERBB2</em> was associated with an increased risk of death and recurrence, HR 2.3 [1.17–4.62], p = 0.0163 and HR 2.07 [1.08–3.98], p = 0.0282, respectively. The literature review identified 19 relevant studies with inconsistent evidence on <em>MECOM’s</em> role in carcinogenesis.</div></div><div><h3>Conclusions</h3><div>ECs with <em>MECOM</em> amplification are associated with poor clinical outcomes, even in the absence of <em>CCNE1</em> or <em>ERBB2</em> amplification. The current literature is limited, and further studies are warranted to determine the role of <em>MECOM</em> amplification in ECs.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101993"},"PeriodicalIF":1.3,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contribution of laparoscopic surgery to the diagnosis of ovarian metastasis from thymoma: A rare case and review of the literature 腹腔镜手术对胸腺瘤卵巢转移诊断的贡献：一例罕见病例及文献回顾

IF 1.3 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports

Pub Date : 2025-11-16 DOI: 10.1016/j.gore.2025.101992

Yui Sejimo , Kenichi Makino , Masato Waga , Enami Kaneko , Takeo Hirakawa , Tae Sugawara , Taichi Yoshida , Hiroyuki Shibata , Hiroshi Nanjo , Yukihiro Terada

Background

Thymoma is a rare mediastinal tumor that usually remains confined to the thoracic cavity. Extrathoracic metastasis is uncommon, and ovarian involvement is extremely rare. Only a few cases have been reported. Laparoscopic surgery provides a minimally invasive option for diagnosis and treatment in such unusual presentations.

Case presentation

A 53-year-old woman with a history of thymoma treated with surgery, chemotherapy, and radiotherapy was found to have a mildly enlarged right ovary and a nodule in the pouch of Douglas five years after initial therapy. Because peritoneal dissemination of thymoma is rare, a primary ovarian tumor was suspected. Diagnostic laparoscopy was performed, resulting in bilateral salpingo-oophorectomy and resection of peritoneal nodules. Histopathology confirmed bilateral ovarian metastases and peritoneal dissemination from thymoma. The patient recovered uneventfully and resumed systemic chemotherapy.

Conclusion

Ovarian metastasis from thymoma is extremely rare but should be considered in patients with a history of thymoma presenting with adnexal masses. This case underscores the diagnostic and therapeutic utility of laparoscopic surgery. Our findings add to the limited literature on extrathoracic spread of thymoma and highlight the role of minimally invasive techniques in such diagnostic challenges.

背景胸腺瘤是一种罕见的纵隔肿瘤，通常局限于胸腔。胸外转移不常见，累及卵巢极为罕见。只有少数病例被报道。腹腔镜手术为诊断和治疗这种不寻常的症状提供了微创的选择。一例53岁女性，胸腺瘤病史，经手术、化疗、放疗治疗，首次治疗5年后发现右卵巢轻度增大，道格拉斯眼袋内有结节。由于胸腺瘤腹膜播散罕见，因此怀疑为原发性卵巢肿瘤。诊断性腹腔镜下行双侧输卵管卵巢切除术及腹膜结节切除术。组织病理学证实双侧卵巢转移和腹膜播散从胸腺瘤。病人平静地恢复并恢复全身化疗。结论胸腺瘤卵巢转移极为罕见，但在有胸腺瘤病史并伴有附件肿物的患者中应予以考虑。本病例强调了腹腔镜手术的诊断和治疗效用。我们的发现增加了胸腺瘤胸外扩散的有限文献，并强调了微创技术在此类诊断挑战中的作用。

{"title":"Contribution of laparoscopic surgery to the diagnosis of ovarian metastasis from thymoma: A rare case and review of the literature","authors":"Yui Sejimo , Kenichi Makino , Masato Waga , Enami Kaneko , Takeo Hirakawa , Tae Sugawara , Taichi Yoshida , Hiroyuki Shibata , Hiroshi Nanjo , Yukihiro Terada","doi":"10.1016/j.gore.2025.101992","DOIUrl":"10.1016/j.gore.2025.101992","url":null,"abstract":"<div><h3>Background</h3><div>Thymoma is a rare mediastinal tumor that usually remains confined to the thoracic cavity. Extrathoracic metastasis is uncommon, and ovarian involvement is extremely rare. Only a few cases have been reported. Laparoscopic surgery provides a minimally invasive option for diagnosis and treatment in such unusual presentations.</div></div><div><h3>Case presentation</h3><div>A 53-year-old woman with a history of thymoma treated with surgery, chemotherapy, and radiotherapy was found to have a mildly enlarged right ovary and a nodule in the pouch of Douglas five years after initial therapy. Because peritoneal dissemination of thymoma is rare, a primary ovarian tumor was suspected. Diagnostic laparoscopy was performed, resulting in bilateral salpingo-oophorectomy and resection of peritoneal nodules. Histopathology confirmed bilateral ovarian metastases and peritoneal dissemination from thymoma. The patient recovered uneventfully and resumed systemic chemotherapy.</div></div><div><h3>Conclusion</h3><div>Ovarian metastasis from thymoma is extremely rare but should be considered in patients with a history of thymoma presenting with adnexal masses. This case underscores the diagnostic and therapeutic utility of laparoscopic surgery. Our findings add to the limited literature on extrathoracic spread of thymoma and highlight the role of minimally invasive techniques in such diagnostic challenges.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101992"},"PeriodicalIF":1.3,"publicationDate":"2025-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0